Cowen reiterated their buy rating on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a report issued on Monday, AnalystRatings.com reports.

A number of other analysts have also weighed in on PIRS. HC Wainwright reiterated a buy rating and issued a $5.00 price objective on shares of Pieris Pharmaceuticals in a research note on Tuesday, March 19th. Zacks Investment Research upgraded shares of Pieris Pharmaceuticals from a hold rating to a buy rating and set a $3.50 price objective on the stock in a research note on Thursday, March 21st. Finally, ValuEngine upgraded shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $5.08.

Shares of Pieris Pharmaceuticals stock opened at $3.88 on Monday. The company has a market cap of $174.49 million, a price-to-earnings ratio of -7.76 and a beta of 1.78. Pieris Pharmaceuticals has a 12-month low of $2.39 and a 12-month high of $6.55.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.05). The business had revenue of $4.91 million during the quarter, compared to analyst estimates of $6.92 million. Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%. Equities research analysts expect that Pieris Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in PIRS. TIAA CREF Investment Management LLC increased its stake in shares of Pieris Pharmaceuticals by 18.6% in the third quarter. TIAA CREF Investment Management LLC now owns 334,082 shares of the biotechnology company’s stock worth $1,871,000 after acquiring an additional 52,302 shares during the period. Vanguard Group Inc. grew its position in Pieris Pharmaceuticals by 13.6% during the third quarter. Vanguard Group Inc. now owns 370,616 shares of the biotechnology company’s stock valued at $2,076,000 after buying an additional 44,335 shares during the period. Marshall Wace LLP grew its position in Pieris Pharmaceuticals by 589.9% during the third quarter. Marshall Wace LLP now owns 161,078 shares of the biotechnology company’s stock valued at $902,000 after buying an additional 137,730 shares during the period. Vanguard Group Inc grew its position in Pieris Pharmaceuticals by 13.6% during the third quarter. Vanguard Group Inc now owns 370,616 shares of the biotechnology company’s stock valued at $2,076,000 after buying an additional 44,335 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Pieris Pharmaceuticals by 433.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 769,551 shares of the biotechnology company’s stock valued at $2,047,000 after buying an additional 625,351 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: Bond

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.